Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2007

View Archived Issues

Neuromed licenses U.S. rights to OROS Hydromorphone

Preclinical profile of the kinase inhibitor R-1530 reported by Roche

Sciele Pharma to acquire Alliant Pharmaceuticals

Novartis delivers Coartem to Tanzania, continues malaria research

KSP inhibition with ARRY-520 shows antitumor activity in animal models of solid tumors

Promising antitumor activity of a novel nonlactone camptothecin derivative

Novel therapeutic agents for respiratory disorders disclosed in recent patent literature

Recent patents describe novel agents for psychopharmacological disorders

BAL-27862 shows promising antitumor activity in multidrug-resistant cancers

PKD inhibition with CRT-0059359 shows potent inhibition of cancer cell growth in vitro

Improved series of class I-selective HDAC inhibitors designed by IRBM/Merck

Novel treatment options for anemia disclosed in recent GSK patents

Enrollment ongoing in phase III study of Medidur for DME

VSF-173 studied in phase II for excessive sleepiness

MP-470 cleared to begin clinical testing

ALKS-27 begins phase IIa study in COPD

CHMP to recommend that occult indication be deleted from Visudyne E.U. label

Exelixis files IND for XL-765

New pediatric eczema study compares EpiCeram to Elidel

Findings from confirmatory study of Foscan in advanced head and neck cancer

BEMA Fentanyl meets primary endpoint in breakthrough cancer pain

XP-13512 shows improvements in RLS

CAM-2029 provides long-acting release of octreotide in phase I study

Preliminary data indicate HyCAMP delivers more cycles of therapy than irinotecan

Nesp approved in Japan

Istradefylline NDA filed for Parkinson's disease

GSK: active start to 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...